12 October 2021 : Original article
Prognostic Role of Serum Albumin Level in Patients with Lymphoma Undergoing Autologous Stem Cell Transplantation
Chengxin Luo12CDE, Qingrong Li12B, Xi Li
3B, Guixian Wu12B, Xiangtao Huang12B, Yali Zhang12B, Yanni Ma12B, Mingling Xie12B, Yanni Sun 12B, Yarui Huang12B, Zhen Huang12B, Shuangnian Xu12AEG*, Jieping Chen12AEG
DOI: 10.12659/AOT.933365
Ann Transplant 2021; 26:e933365
Table 4 Results of univariate and multivariate Cox regression analyses for progression-free survival in the B-cell non-Hodgkin lymphoma subgroup.
| Characteristics | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95%CI) | P | HR (95%CI) | P | |
| Male | 2.07 (0.87–4.91) | 0.100 | ||
| Age >60 | 3.37 (1.41–8.06) | 0.006* | 4.06 (1.67–9.86) | 0.002* |
| BMI <18.5 | 0.04 (0.00–13.61) | 0.283 | ||
| ECOG PS 2–3 | 1.75 (0.81–3.80) | 0.154 | ||
| Ann Arbor stage III–IV | 1.47 (0.85–2.57) | 0.172 | ||
| B symptoms | 0.99 (0.45–2.22) | 0.988 | ||
| IPI risk | ||||
| Low | 1.00 | |||
| Low-intermediate | 1.46 (0.52–4.15) | 0.474 | ||
| High-intermediate | 1.68 (0.51–5.53) | 0.390 | ||
| High | 3.39 (1.13–10.18) | 0.029* | ||
| LDH elevation (>240 U/L) | 2.52 (1.18–5.40) | 0.017* | ||
| Bone marrow involvement | 3.09 (1.16–8.24) | 0.024* | ||
| Prior regimens | ||||
| <5 | 1.00 | |||
| 5–10 | 1.40 (0.60–3.25) | 0.432 | ||
| ≥10 | 1.11 (0.53–2.35) | 0.783 | ||
| Rituximab induction | 0.96 (0.44–2.09) | 0.909 | ||
| PR or NR | 2.65 (1.21–5.80) | 0.015* | ||
| Disease duration | 1.00 (0.98–1.02) | 0.711 | ||
| Albumin <37 g/L | 3.29 (1.47–7.37) | 0.004* | 3.22 (1.42–7.29) | 0.005* |
| TP <60 g/L | 2.81 (1.26–6.27) | 0.012* | ||
| Globulin level | 0.95 (0.87–1.03) | 0.186 | ||
| Albumin/globulin ratio | 0.90 (0.29–2.82) | 0.862 | ||
| Conditioning regimen | ||||
| BEAM | 1.00 | |||
| BEAC | 1.23 (0.36–4.24) | 0.738 | ||
| CBV | 1.05 (0.32–3.50) | 0.935 | ||
| CHOP-like | 0.75 (0.20–2.80) | 0.667 | ||
| Dose of infused mononuclear cells | 0.97 (0.81–1.16) | 0.712 | ||
| Maintenance therapy | 1.12 (0.50–2.49) | 0.782 | ||
| * B-NHL – B-cell non-Hodgkin lymphoma; BEAC – carmustine, etoposide, cytarabine, and cyclophosphamide; BEAM – carmustine, etoposide, cytarabine, and melphalan; BMI – body mass index; CHOP – cyclophosphamide, anthracycline, vincristine, and prednisone; CBV – cyclophosphamide, carmustine, and etoposide; CR – complete remission; ECOG PS – Eastern Cooperative Oncology Group performance status; HL – Hodgkin lymphoma; HR – hazard ratio; IPI – international prognostic index; LDH – lactate dehydrogenase; NHL – non-Hodgkin lymphoma; NR – no response; PFS – progression-free survival; PR – partial remission; TP – total protein. | ||||